Cagiano R, Barfield R J, White N R, Pleim E T, Cuomo V
Institute of Pharmacology, University of Bari, Italy.
Pharmacol Biochem Behav. 1989 Sep;34(1):53-8. doi: 10.1016/0091-3057(89)90352-3.
We investigated the role of dopamine receptor subtypes in the regulation of ultrasonic vocalization and masculine copulatory behavior. Intact sexually experienced male Long-Evans rats were treated with saline, selective dopamine D1 (SKF 38393) and D2 (LY 171555) receptor agonists and with selective dopamine D1 (SCH 23390) and D2 (raclopride) receptor antagonists 15 and 30 min before the 30-min test session, respectively. Mating stimuli were ovariectomized female rats injected SC with estradiol benzoate (8 micrograms/0.1 ml/rat) and progesterone (200 micrograms/0.1 ml/rat), 48 and 4 hr before the test session, respectively. We found a decrease in the number of intromissions required to reach ejaculation in animals treated with SKF 38393 (10 mg/kg/IP), LY 171555 (doses ranging from 0.01 to 0.5 mg/kg/SC) and with raclopride (0.1 mg/kg/SC). LY 171555 reduced the postejaculatory vocalization (PEV) in a dose-dependent fashion with complete suppression at the highest dose. No other parameters of sexual behavior were affected by this treatment. Raclopride, a dopamine D2 receptor antagonist, antagonized the suppressive effects of the D2 agonist LY 171555 on the PEV (and also decreased the number of intromissions to reach ejaculation), whereas SCH 23390, a dopamine D1 receptor antagonist, did not. Raclopride, given alone at the dose of 0.5 mg/kg/SC, almost completely suppressed all behavioral activity, whereas the lower dose (0.1 mg/kg) decreased intromission frequency and increased the length of the 22 kHz PEV. Therefore, we suggest that 22 kHz PEV is under the control of dopamine D2 receptors.
我们研究了多巴胺受体亚型在调节超声发声和雄性交配行为中的作用。性经验丰富的完整雄性Long-Evans大鼠,分别在30分钟测试期前15分钟和30分钟,用生理盐水、选择性多巴胺D1(SKF 38393)和D2(LY 171555)受体激动剂以及选择性多巴胺D1(SCH 23390)和D2(雷氯必利)受体拮抗剂进行处理。交配刺激是在测试期前48小时和4小时分别皮下注射苯甲酸雌二醇(8微克/0.1毫升/只大鼠)和孕酮(200微克/0.1毫升/只大鼠)的去卵巢雌性大鼠。我们发现,用SKF 38393(10毫克/千克/腹腔注射)、LY 171555(剂量范围为0.01至0.5毫克/千克/皮下注射)和雷氯必利(0.1毫克/千克/皮下注射)处理的动物,达到射精所需的插入次数减少。LY 171555以剂量依赖性方式减少射精后发声(PEV),在最高剂量时完全抑制。该处理未影响性行为的其他参数。多巴胺D2受体拮抗剂雷氯必利拮抗了D2激动剂LY 171555对PEV的抑制作用(并且也减少了达到射精的插入次数),而多巴胺D1受体拮抗剂SCH 23390则没有。单独以0.5毫克/千克/皮下注射剂量给予雷氯必利,几乎完全抑制了所有行为活动,而较低剂量(0.1毫克/千克)则降低了插入频率并增加了22千赫兹PEV的时长。因此,我们认为22千赫兹PEV受多巴胺D2受体的控制。